CN121534035A - 大麻二酚酸酯类组合物及其用途 - Google Patents

大麻二酚酸酯类组合物及其用途

Info

Publication number
CN121534035A
CN121534035A CN202511437638.6A CN202511437638A CN121534035A CN 121534035 A CN121534035 A CN 121534035A CN 202511437638 A CN202511437638 A CN 202511437638A CN 121534035 A CN121534035 A CN 121534035A
Authority
CN
China
Prior art keywords
cbda
receptor
nausea
rats
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511437638.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·梅舒朗
L·帕克
R·帕特维
A·韦勒
J·塔姆
C·哈吉
R·斯莫姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
University of Guelph
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical University of Guelph
Publication of CN121534035A publication Critical patent/CN121534035A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202511437638.6A 2017-06-20 2018-06-20 大麻二酚酸酯类组合物及其用途 Pending CN121534035A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762522243P 2017-06-20 2017-06-20
US62/522,243 2017-06-20
PCT/IL2018/050678 WO2018235079A1 (en) 2017-06-20 2018-06-20 CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF
CN201880041597.0A CN111032088A (zh) 2017-06-20 2018-06-20 大麻二酚酸酯类组合物及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880041597.0A Division CN111032088A (zh) 2017-06-20 2018-06-20 大麻二酚酸酯类组合物及其用途

Publications (1)

Publication Number Publication Date
CN121534035A true CN121534035A (zh) 2026-02-17

Family

ID=62875079

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511437638.6A Pending CN121534035A (zh) 2017-06-20 2018-06-20 大麻二酚酸酯类组合物及其用途
CN201880041597.0A Pending CN111032088A (zh) 2017-06-20 2018-06-20 大麻二酚酸酯类组合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880041597.0A Pending CN111032088A (zh) 2017-06-20 2018-06-20 大麻二酚酸酯类组合物及其用途

Country Status (12)

Country Link
US (1) US11440870B2 (https=)
EP (1) EP3509638B1 (https=)
JP (1) JP2020524679A (https=)
CN (2) CN121534035A (https=)
AU (1) AU2018287018B2 (https=)
BR (1) BR112019026916A2 (https=)
CA (1) CA3067512A1 (https=)
DK (1) DK3509638T3 (https=)
ES (1) ES2909350T3 (https=)
MX (1) MX389847B (https=)
PT (1) PT3509638T (https=)
WO (1) WO2018235079A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
PT3509638T (pt) 2017-06-20 2022-03-02 Univ Guelph Composições de ésteres de ácido canabidiólico e suas utilizações
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
US20220054380A1 (en) * 2018-12-25 2022-02-24 Epm (Ip), Inc. Cannabidioloic acid esters for cosmetic or edible compositions
KR20210151816A (ko) * 2019-03-12 2021-12-14 이피엠 (아이피), 인코포레이티드 칸나비노이드 산 에스테르 조성물 및 이의 용도
JP2022545491A (ja) 2019-08-22 2022-10-27 イーピーエム（アイピー）， インコーポレイテッド カンナビノイド酸エステル組成物およびその使用
WO2021137224A1 (en) * 2020-01-01 2021-07-08 Epm Group, Inc. Cannabidiolic acid esters for treating muscular dystrophy
IL275108A (en) * 2020-06-03 2022-01-01 Epm Ip Inc Abnormal acid cannabidiol (abn-cbd) derivatives and their uses
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
IL303739A (en) * 2020-12-24 2023-08-01 Buzzelet Development And Technologies Ltd Compositions including cannabinoid esters
US20230066947A1 (en) * 2021-08-04 2023-03-02 Max Hammond Method for the augmentation of substance abuse therapies using cannabinoid formulations

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2318468A1 (fr) * 1975-07-17 1977-02-11 Jaeger Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres
US5342971A (en) 1992-12-29 1994-08-30 The Australian National University Process for the preparation of dibenzo[b,d]pyrans
WO1999057107A2 (en) 1998-05-04 1999-11-11 The University Of Connecticut Cannabinoids selective for the cb2 receptor
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
US20050287180A1 (en) 2004-06-15 2005-12-29 Chen Andrew X Phospholipid compositions and methods for their preparation and use
CN102766128A (zh) 2005-09-29 2012-11-07 阿尔巴尼分子研究公司 δ-9-四氢大麻酚的生成方法
CN101384012B (zh) * 2008-10-22 2012-05-23 华为终端有限公司 系统端和终端的交互媒体文档更新方法及装置
DE102009019322A1 (de) * 2009-04-30 2010-11-11 The Health Concept Gmbh Verfahren zur Herstellung von Synthetischen Cannabinoiden
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB2515312A (en) 2013-06-19 2014-12-24 Gw Pharma Ltd The use of phytocannabinoids in the treatment of ovarian carcinoma
EP2842933B1 (de) * 2013-09-03 2015-07-29 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
EP3131874B1 (en) * 2014-04-16 2018-07-25 Emerald Health Pharmaceuticals Inc. Novel cannabidiol quinone derivatives
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
GB2531283A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiols in the treatment of degenerative skeletal muscle diseases
EP3061450A1 (de) 2015-02-26 2016-08-31 Symrise AG Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CN106810426B (zh) 2016-12-29 2020-05-08 暨明医药科技（苏州）有限公司 一种大麻二酚的合成方法
PT3509638T (pt) 2017-06-20 2022-03-02 Univ Guelph Composições de ésteres de ácido canabidiólico e suas utilizações
WO2019234728A1 (en) 2018-06-04 2019-12-12 Al&Am Pharmachem Ltd. Cannabinolic acid derivatives and uses thereof

Also Published As

Publication number Publication date
US11440870B2 (en) 2022-09-13
JP2020524679A (ja) 2020-08-20
AU2018287018B2 (en) 2022-04-28
US20200115317A1 (en) 2020-04-16
MX2019015311A (es) 2022-02-02
CN111032088A (zh) 2020-04-17
BR112019026916A2 (pt) 2020-06-30
DK3509638T3 (da) 2022-04-11
AU2018287018A1 (en) 2020-01-30
CA3067512A1 (en) 2018-12-27
WO2018235079A1 (en) 2018-12-27
EP3509638A1 (en) 2019-07-17
EP3509638B1 (en) 2022-01-12
PT3509638T (pt) 2022-03-02
ES2909350T3 (es) 2022-05-06
MX389847B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
CN121534035A (zh) 大麻二酚酸酯类组合物及其用途
US10617733B2 (en) Orally consumable cannabinoid composition including lecithin
US7179800B2 (en) Cannabinoids
EP2986289B1 (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
US20090306221A1 (en) Use for Cannabinoid
US20230218567A1 (en) Compound and method for treating diseases and disorders
WO2022103650A1 (en) Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
CN105849111A (zh) 吡喃并秋葵纤维异甲酚衍生物以及代谢综合征或炎症疾病治疗用药学组成物
JP2007526328A (ja) 単独および抗うつ薬と組み合わせた形のＣｏｘ−２阻害剤によって精神障害を治療または予防するための方法および組成物
CN102274227A (zh) 粉防己碱在制备预防和/或治疗抑郁症药物中的应用
TW200424153A (en) Pharmaceutical composition
Zhang et al. A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo
CN101379063A (zh) 3,9-二氮杂双环[3.3.1]壬烷衍生物及其作为单胺神经递质再摄取抑制剂的用途
WO1999026612A1 (en) Novel cannabinoid receptor modulators
Class et al. Patent application title: CANNABIDIOLIC ACID ESTERS COMPOSITIONS AND USES THEREOF Inventors: Raphael Mechoulam (Jerusalem, IL) Linda Parker (Campbell River, British Columbia, CA) Roger Pertwee (Aberdeen, Scotland, GB) Aron Weller (Shoham, IL) Joseph Tam (Jerusalem, IL) Christeen Haj (Nazareth Hit, IL) Reem Smoum (Jerusalem, IL)
HK40028173A (en) Cannabidiolic acid esters compositions and uses thereof
MX2012002551A (es) Compuestos para tratar desordenes o enfermedades asociados con la actividad del receptor de neuroquinina 2.
RU2412184C2 (ru) Соли производного пиперазина с салициловой и гентизиновой кислотами
US20110319490A1 (en) Methods and compositions for the treatment of irritable bowel syndrome
WO2022254006A1 (en) Cannabidiol for use in the treatment of pain resulting from an indoleamine 2,3-dioxygenase-1 (ido1) related disease
US20250241934A1 (en) Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders
WO2023224960A1 (en) Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
MX2011002727A (es) Composicion farmaceutica novedosa para tratamiento de dolor nociceptivo.
ZA200605058B (en) 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination